Browse the evidence

GLP-1 receptor agonists may have disease-modifying effects on osteoarthritis and osteoporosis by reducing inflammation and promoting bone formation.

If you have joint pain or weak bones, ask your doctor if your GLP-1 medication might offer extra protection. While weight loss is the main benefit, these drugs may also reduce inflammation in joints and help maintain bone density.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of hepatic decompensation events in patients with type 2 diabetes and compensated cirrhosis compared to DPP4 inhibitors and sulfonylureas.

If you have type 2 diabetes and compensated cirrhosis, GLP-1 receptor agonists may help reduce your risk of serious liver complications like fluid buildup or bleeding compared to other common diabetes medications. Discuss the benefits and risks with your doctor.

In obese or overweight individuals with low glucose effectiveness (Sg), subclinical reactive hypoglycemia (SRH) acts as a biological driver for frequent snacking, creating a vicious cycle that promotes obesity.

If you struggle to stop snacking despite gaining weight, it may not be a failure of willpower but a metabolic response. Specifically, if you have low glucose effectiveness, your body may drop into subclinical hypoglycemia after meals, triggering intense hunger to protect your brain. To break this cycle, focus on lifestyle factors that improve glucose effectiveness, such as regular walking (≥8000 steps/day) and reducing high-fat/sugar intake, rather than relying solely on willpower to resist snacks.

Menstrual cycle symptoms are widespread and severe in resistance-trained athletes, with 92% reporting symptoms and 76% reporting cramps, yet MC irregularities are not more common than in the general exercising population.

Expect menstrual symptoms like cramps and fatigue to be common (92% prevalence) regardless of your competitive level. However, do not assume your resistance training is causing irregular periods; your cycle regularity is likely similar to other women. Focus on managing the high prevalence of symptoms (like cramps and fatigue) through tracking and potentially hormonal or lifestyle interventions.

GLP-1 receptor agonists (GLP-1 RAs) reduce alcohol consumption and craving in patients with Alcohol Use Disorder (AUD) by modulating the mesolimbic dopamine reward pathway.

If you have AUD, especially if you also have obesity or Type 2 Diabetes, GLP-1 medications (like Semaglutide) may help reduce your alcohol intake and cravings by affecting brain reward pathways. This is an emerging off-label use, so discuss it with your doctor, particularly if standard treatments have failed or caused side effects.

GLP-1 agonists do not directly cause acne vulgaris; reported acne-like symptoms are likely injection-site hypersensitivity reactions or secondary to weight-loss-induced hormonal changes (e.g., IGF-1 increases).

If you are using a GLP-1 agonist and develop acne, it is likely not the drug directly attacking your skin. Instead, the weight loss you are experiencing may trigger hormonal shifts (like increased IGF-1) that worsen acne. Alternatively, any lumps you see are likely injection-site reactions, not acne. Consult your doctor to distinguish between these causes.

GLP-1 receptor agonists (GLP-1 RAs) reduce systemic and intestinal inflammation in Inflammatory Bowel Disease (IBD) by modulating immune cell signaling, enhancing the intestinal epithelial barrier, and improving gut microbiota composition.

If you have IBD and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight loss or diabetes, current evidence suggests they may actually help your gut health by reducing inflammation and lowering the risk of surgery. Start with a low dose and titrate slowly to manage nausea. Monitor your symptoms, but know that studies show these drugs do not increase the risk of IBD flares or hospitalizations compared to other diabetes medications. If you are underweight, discuss this carefully with your doctor, as the primary benefit in obese IBD patients is well-documented.

Long-term use of incretin agonists shows attenuated efficacy over time, with weight loss and HbA1c improvements diminishing significantly in the 3rd to 7th year of treatment.

If you are on incretin medication for several years, you may notice that the weight loss and blood sugar improvements slow down or plateau. This is a known biological response (tachyphylaxis). It does not mean the drug has stopped working entirely, but it may require dose adjustments or intensified lifestyle efforts to maintain benefits.

Tirzepatide may reduce the risk of atherosclerosis progression through lipid-lowering, anti-inflammatory, and improved insulin sensitivity mechanisms, offering cardioprotective benefits beyond glycemic control.

Tirzepatide not only lowers blood sugar and helps with weight loss but may also protect your heart and blood vessels by reducing inflammation and improving lipid levels. This is especially important if you have diabetes and heart disease.

Native gut-produced GLP-1 exerts central anorectic effects via a neuroendocrine signaling mechanism involving the portal vein and vagal afferent nerves, without entering the brain.

Your body naturally produces GLP-1 after eating, which signals fullness to your brain via the vagus nerve. This is a fast, efficient system that doesn't require the hormone to cross into the brain tissue, explaining why synthetic GLP-1 drugs mimic this natural process effectively.

Roux-en-Y gastric bypass (RYGB) surgery produces distinct circulating metabolite signatures (specifically higher propionate and conjugated bile acids in good responders) that correlate with weight loss response, independent of gut microbiota composition or hunger/satiety hormone levels.

If you are considering or have had gastric bypass surgery, know that 'success' isn't just about how much weight you lose. The surgery changes your body's chemistry (specifically bile acids and gut byproducts like propionate) in ways that might improve your metabolism even if the scale doesn't move as much as expected. This means metabolic health improvements can happen independently of massive weight loss, and tracking these internal markers might be more important than just the number on the scale.

Preclinical evidence indicates that GLP-1 RAs directly improve skeletal muscle quality by reducing intramuscular fat (myosteatosis), enhancing mitochondrial biogenesis, and suppressing inflammatory markers, independent of weight loss.

Animal studies suggest GLP-1 drugs may improve the 'quality' of your muscle cells by boosting mitochondria and reducing inflammation. While this doesn't mean you'll build bigger muscles without exercise, it may help your muscles function better and recover faster, especially if you have diabetes or obesity.

GLP-1 receptor agonists exert direct anabolic and protective effects on skeletal muscle tissue, including promoting myogenesis, enhancing mitochondrial function, and reducing inflammation, which may help preserve muscle quality despite lean mass loss.

The drug may actively help protect muscle quality at a cellular level, but this does not guarantee muscle mass preservation without active lifestyle interventions.

Cerebral CCK acts as a neurotransmitter involved in memory and anxiety regulation, with knockout mice showing memory loss and increased anxiety, while exogenous CCK administration can induce panic attacks.

CCK is not just a gut hormone; it works in the brain to regulate anxiety and memory. While high doses can induce panic, natural CCK signaling may help modulate these states. This highlights the gut-brain axis.

Bariatric surgery (Roux-en-Y gastric bypass) reduces the incidence of heart failure by 2-5 times compared to non-surgical patients, as observed in large Swedish registries.

Bariatric surgery significantly lowers the risk of developing heart failure (by 2-5 times) compared to non-surgical management in obese patients.

Calorie restriction-induced weight loss does not restore or alter the secretion of appetite-inhibiting gut hormones (GLP-1, PYY, CCK, GIP, NT, SST) or their gene expression in the small intestine of obese subjects.

If you have lost weight, do not expect your hunger hormones to normalize. Your body may still signal hunger as strongly as it did when you were heavier. This biological persistence is a key reason for weight regain, so you must rely on external strategies (dietary structure, behavioral habits) to manage appetite, as your internal hormonal signals will not naturally support maintenance.

In individuals with normal glucose tolerance (NGT), carbohydrate-modified diets (low glycemic load or high fiber) do not provide a significant weight loss advantage over high-carbohydrate or control diets, and may even result in greater weight regain on high glycemic load diets.

If you have normal blood sugar levels, switching to a low-carbohydrate or low-glycemic diet is unlikely to give you a weight loss advantage over a standard balanced diet. You may even regain weight faster if you switch to a high-glycemic diet, but a low-glycemic diet offers no special benefit. Focus on sustainable eating habits rather than strict carbohydrate restriction.

Obesity-related complications (ORCs) such as hypertension, diabetes, and dyslipidemia are the primary drivers for initiating pharmacological obesity treatment, often delaying preventative care until complications are present and uncontrolled.

If you have obesity, do not wait for complications like high blood pressure or diabetes to seek treatment. The current system often delays medication until these issues arise, but early intervention with Obesity Management Medications (OMMs) can help control these complications and improve quality of life. Discuss preventative treatment with your doctor, especially if you have a family history of these conditions.

Gold-standard T2DM medications (metformin, SGLT2 inhibitors, GLP-1 agonists) modulate the redox state of skeletal muscle, potentially restoring metabolic function and insulin sensitivity.

Standard diabetes medications like metformin and GLP-1 agonists do more than lower blood sugar; they also interact with the redox state of your muscles. This interaction may help restore insulin sensitivity, offering a benefit beyond simple glycemic control.

Administration of the triple agonist peptide GEP44 to diet-induced obese rats produces greater reductions in body weight and food intake compared to the GLP-1 receptor agonist liraglutide, while avoiding the nausea and malaise associated with high-dose GLP-1RAs.

This preclinical data suggests that combining GLP-1 activity with Neuropeptide Y1 and Y2 receptor agonism may offer a path to more effective weight loss than current GLP-1 drugs alone, potentially without the common side effect of nausea. This is not yet a human treatment but highlights a promising direction for peptide-based obesity therapies.

GEP44 promotes insulin-independent glucose uptake in muscle tissue via Y1 receptor agonism, distinct from the insulin-dependent pathway.

This mechanism suggests that future obesity drugs might improve blood sugar control in muscles even without triggering insulin release, potentially offering benefits for insulin resistance.

Semaglutide use is associated with oral adverse effects, specifically xerostomia (dry mouth) and hyposalivation, likely due to prolonged GLP-1 receptor activation disrupting salivary gland signaling.

If you are taking semaglutide and experience persistent dry mouth, do not assume it is solely due to dehydration. The drug's prolonged action on salivary glands can reduce saliva production directly. Consult your provider for preventive oral care strategies to manage this side effect.

Preoperative use of GLP-1 and GLP-1/GIP receptor agonists significantly reduces surgical site infections, wound dehiscence, and thromboembolic events in patients undergoing elective hernia repair.

If you are scheduled for hernia surgery and take GLP-1 drugs like Ozempic or Mounjaro, do not stop them abruptly without talking to your surgical team. Recent data shows they actually lower your risk of infection and blood clots. Your doctors can use a simple ultrasound on your stomach before anesthesia to check if it's safe to proceed, potentially saving you from stopping a medication that is helping your overall health.

Older adults may experience higher rates of adverse events and treatment intolerance with AOMs compared to younger adults, particularly gastrointestinal issues and risks related to dehydration and falls.

Be aware that older adults may experience more side effects from weight loss medications, such as nausea or dizziness. This can lead to dehydration or falls. It is important to work closely with a doctor to manage these side effects.